Anemia during pregnancy and treatment with intravenous iron: review of the literature

Bashiri, Asher; Burstein, Eliezer; Sheiner, Eyal; Mazor, Moshe

doi:10.1016/s0301-2115(03)00113-1

Cited by 105 publications

(90 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The tolerance and effi cacy of ferric carboxymaltose has been demonstrated previously in several studies for different groups of patients with iron-defi ciency anemia [3,4,7,8,14,19,21] with similar results. Bailie GR [3] showed in a review paper, including nine randomized studies with more than 3000 patients, that ferric carboxymaltose had a good tolerability and effi ciency profi le.…”

Section: Side Effects and Tolerancesupporting

confidence: 74%

Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose

Christoph

Schüller²,

Studer³

et al. 2012

Journal of Perinatal Medicine

103

102

View full text Add to dashboard Cite

Objective: Oral iron substitution has shown to be insuffi cient for treatment of severe iron defi ciency anemia in pregnancy. Ferric carboxymaltose is a new intravenous (i.v.) iron formulation promising to be more effective and as safe as iron sucrose. We aimed to assess side effects and tolerance of ferric carboxymaltose compared to i.v. iron sucrose in pregnant women. Methods:We performed a retrospective analysis of 206 pregnant women who were treated either with ferric carboxymaltose or iron sucrose for iron-defi ciency anemia with into lerability to oral iron substitution, or insuffi cient hemoglobin increase after oral iron treatment, or need for rapid hemoglobin reconstitution. Primary endpoint was to evaluate the maternal safety and tolerability. Secondary endpoint was to assess effi cacy of the treatment and exclude safety concerns for the fetus. Results: The incidence of drug-related adverse events was low and mostly mild in both groups. Mild adverse events occurred in 7.8 % for ferric carboxymaltose and in 10.7 % for iron sucrose. The mean rise of hemoglobin value was 15.4 g/L for ferric carboxymaltose and 11.7 g/L for iron sucrose. Conclusion: Ferric carboxymaltose administration in pregnant women is well tolerated and is not associated with any relevant clinical safety concerns. Ferric carboxymaltose has a comparable safety profi le to iron sucrose but offers the advantage of a much higher iron dosage at a time reducing the need for repeated applications and increasing patients ' comfort. Ferric carboxymaltose is the drug of choice, if i.v. iron treatment becomes necessary in the second or third trimester of pregnancy.

show abstract

Section: Side Effects and Tolerancesupporting

confidence: 74%

Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose

Christoph

Schüller²,

Studer³

et al. 2012

Journal of Perinatal Medicine

103

102

View full text Add to dashboard Cite

show abstract

“…There are very few safety studies available concerning the use of iron dextrin and has a less clinical experience, hence less confidence in clinical settings. 1,15,23 Whereas iron sucrose has well-established efficacy and safety profile as a IV iron preparation. Iron sucrose is readily available for the erythropoiesis and replenishes the iron store.…”

Section: Discussion Discussion Discussion Discussionmentioning

confidence: 99%

“…Other parenteral iron preparations available are ferric gluconate and ferric citrate but are found to cause severe and extended liver necrosis. 1,23 However, two factors are associated which limits the use of intravenous iron therapy, first is the cost compared with oral iron and second is the increase in hospital stay, but it is again linked to the better patient's compliance and faster recovery.…”

Section: Discussion Discussion Discussion Discussionmentioning

confidence: 99%

“…The prevalence of anemia in world population is estimated between 20 and 50%. [1][2][3] The World Health Organization data presented at International Federation of Gynecology and Obstetrics (FIGO) meeting held in 2003 at Chile, reported around 500,000 maternal death and 20,000,000 morbidity cases per year related to iron deficiency and anemia. The major cause of the higher anemia prevalence in India is malnutrition due to lower socioeconomic background, higher incidences of hook worm infection, malaria and poor availability of iron 6,7,10,11 majorly in rural area.…”

Section: Introduction Introduction Introduction Introductionmentioning

confidence: 99%

“…In addition, iron sucrose complex has high availability for erythropoiesis, less renal excretion, and tissue accumulation is less and less chances of toxicity. 1,[15][16][17] …”

Section: Introduction Introduction Introduction Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intravenous Iron Therapy versus Oral Iron in Postpartum Patients in Rural Area

Verma¹,

Inamdar²,

Malhotra³

2011

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Objectives: The aim of this study is to evaluate the efficiency and safety of intravenous iron sucrose complex and comparison with oral iron therapy in postpartum period in rural area. Materials and methods:It is a prospective, randomized, hospital-based clinical study carried out in over 150 patients, having Hb < 8 mg/dl after 24 hours of delivery. 600 to 800 mg iron sucrose has been given in divided doses, 200 mg on alternate day in 100 ml of normal saline to half of the patients whereas rest of the patients given 200 mg bd dose of ferrous sulphate by oral route for one month. Data was collected after 1st, 2nd, 3rd and 4th week for the hemoglobin estimation and assessment of the impact of intravenous iron sucrose treatment on the postpartum parameters. Results:The mean Hb was significantly increased in the intravenous iron sucrose group in 7 days (7.42 ± 1.04 gm/dl to 9.8 ± 0.76 gm/dl) of treatment but there was no change observed in mean Hb in the patients treated with oral ferrous sulphate. Women treated with intravenous iron sucrose has shown significantly higher Hb on day 7, day 15 and day 30 as compared to the women those were treated with oral iron (p < 0.0001). Conclusion:Overall intravenous iron sucrose appears to be an effective mode of treatment in postpartum patients with no serious side effects and associated with faster recovery in shorter duration of hospital stay than oral iron treatment.

show abstract